Minimal residual disease (MRD) after therapy has unequivocal prognostic value in acute myeloid leukemia. There is growing evidence that the presence of MRD detected by multiparametric flow cytometry (MFC) and quantitative polymerase chain reaction (qPCR)-based methods, has improved the assessment of treatment response and risk stratification for clinical management. New molecular methods, such as high-throughput next-generation sequencing (NGS), have evolved into routine laboratory tools to improve the sensitivity and specificity of MRD detection. In this talk, Dr. Chen reviews the methodological approaches of MRD detection, discusses the clinical implications of MRD in risk stratification and suggests potential areas for future investigation.

After viewing this lecture, participants should be able to:
1. Describe the methodological principles of minimal residual disease testing in acute myeloid leukemia.
2. Recognize the advantages and limitation of different methods for minimal residual disease testing.
3. Discuss the implications of minimal residual disease in prognosis and treatment of acute myeloid leukemia.

Xueyan Chen, MD, PhD, assistant professor, Department of Laboratory Medicine, associate director, Hematopathology Laboratory, UW

10/10/2017

[ Ссылка ]
[ Ссылка ]

свернуть